Stream

Join this community to post or comment

Jeff Kang
owner

Discussion  - 
 
>RepliCel Receives European Patent for its Innovative Dermal Injector Technology

RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic per procedure, and the enhanced treatment of fine wrinkles of the face, décolleté and hands

VANCOUVER, BC – January 11, 2016 – RepliCel Life Sciences Inc.
(OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has been granted a patent (EP2623146) by the European Patent Office for its injection device technologies.

The first device being developed under this patent, RCI-02, is designed for injecting hyaluronic acid as a dermal filler.
The device is also being developed for the injection of RepliCel’s RCH-01 hair restoration and RCS-01 skin rejuvenation products.
Future iterations of the technology and device will be optimized for other injectables such as drugs, vaccines, fat grafts, etc.

“This patent grant is an important milestone for the company as it underpins the commercial value of RCI-02 for the delivery of other injectables beyond our own products.
RCI-02 coupled with an application in the area of hyaluronic acid (HA) represents an early opportunity for licensing and revenue,” stated RepliCel CEO Lee Buckler.

Overall benefits of this next-generation dermal injector technology include improved handling, reduction or elimination of the need for local anesthetic, quicker procedure times, an expectation of more consistent clinical results because of the injector’s controls, and a significant expansion of the areas that can be addressed with dermal fillers due to the ability to conduct broad, shallow, and evenly-dispersed injections.
Additionally, it is expected that a whole new class of injection specialists may be enabled to perform certain dermal injection procedures due to the device’s simplicity and programmability.

“RCI-02 was originally conceived to deliver our cellular products; however, we believe this device will have a profound impact on all dermal injections – particularly in the cosmetic dermal injection market,” commented Dr.
Rolf Hoffmann, RepliCel’s Chief Medical Officer, who is a practicing dermatologist and remains the visionary for the RCI-02 injector.
“Dermatologists have been hindered for years by a single needle syringes’ inability to precisely deliver approved dermal fillers into fine wrinkles of the face, décolleté, and hands.
RCI-02 is designed to address these unserved markets while also improving on current markets by enabling precise and repeatable delivery of injectable substances.
RCI-02 will enable clinicians to better control injection consistency while also enabling less skilled clinicians to undertake these procedures with the desired results.”

“Overall, we expect RCI-02 will increase the market for existing cosmetic injectables by expanding their use into applications not previously addressable, shortening procedure times, and improving both patients’ experience and cosmetic results.
We believe ensuring the optimal and controlled delivery of our cell-based products is an important component to the commercial value we are creating around the development of our products for both aging or sun damaged skin and pattern baldness,” commented Lee Buckler, CEO.

About RCI-02

The RCI-02 injector was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes.



RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic per procedure, and the enhanced treatment of fine wrinkles of the face, décolleté and hands VANCOUVER, BC – January 11, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development of autologous cell …
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
"In the tendinopathic regions, compared to the flanking healthy tissue, we observed
1) an increase in the ratio of collagen III:I proteins,
2) buckling of the collagen fascicles in the extracellular matrix,
3) buckling of tenocytes and their nuclei, and
4) an increase in the ratio small:large diameter collagen fibrils.
In summary, load-induced non-rupture tendinopathy in humans is associated with localized biochemical changes, a shift from large to small diameter fibrils, buckling of the tendon extracellular matrix, and buckling of the cells and their nuclei."
 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981497/
Achilles tendinopathies display focal tissue thickening with pain and ultrasonography changes. Whilst complete rupture might be expected to induce changes in tissue organization and protein composition, little is known about the consequences of non-rupture-associated ...
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
Echometrix moves new ultrasound technology from animals to humans – (EchoSoft give quantitative data about mechanical characteristics and properties, like stiffness, and about the status of musculoskeletal (tendon and ligament) tissue)
Echometrix is seeking subjects in the Madison, WI area with a tennis elbow diagnosis. If you have tennis elbow and would like to participate in a test...
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
>"After ten years of scientific research, Japanese personal care player, Shiseido has patented its RepliCel Hair-01 (RCH-01) hair regeneration technology." (autologous cell transplantation)
After ten years of scientific research, Japanese personal care player, Shiseido has patented its RepliCel Hair-01 (RCH-01) hair regeneration technology.
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
>RepliCel is a regenerative medicine innovator that has been among the first in the world to create formal ties with Japanese industry to leverage this rapidly emerging opportunity.
In 2013, it signed a major deal with Shiseido Company for commercialization of its autologous cell therapy (produced using cells harvested from the patient's own hair follicles) for treating pattern baldness.
The agreement granted an exclusive license for RepliCel’s most advanced product, RCH-01, to Shiseido for certain Asian countries.
 
Mr.
Youichi Shimatani, Shiseido’s Chief Corporate Officer for Research and Development commented, “Creating beauty in everyday life is the mission of Shiseido.
To alleviate suffering of people with alopecia, we have dedicated many years to hair research.
Using the knowledge and technologies acquired from our research activities, Shiseido is currently preparing to launch an RCH-01 clinical research study for the treatment of pattern baldness under the supervision of key clinical opinion leaders of hair research in Japan.” In his opinion, “Japan’s new Regenerative Medicine Law allows industry partners like Shiseido to take part in clinical research under clinical guidance to develop new regenerative therapies.
We hope that our efforts will lead to further promotion and advancement of regenerative medicine in Japan.”
 
RepliCel holds a unique and strong competitive position in Japan, Buckler notes, because the deal with Shiseido was signed shortly before Japan’s new regulations were finalized in November 2014.
Two nations, different strategies, one goal: addressing incurable medical conditions
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
RCT-01 Chronic Achilles Tendinosis Clinical Trial Sign-up

RepliCel appreciates your interest in our clinical trial programme.
 We will be conducting a clinical research study at the University of British Columbia on an experimental cell therapy product as a potential treatment for chronic tendinosis of the Achilles tendon (Achilles tendinosis).

To learn more about and determine if you would qualify for participation in this trial please visit http://www.tendonstudy.com

Have you suffered from chronic pain in your Achilles tendon for more than six months?
If you do, you might be suffering from chronic Achilles tendinosis.

Chronic Achilles tendinosis is a degenerative disease of the tendon.
It is caused by a cycle of injury, improper healing and re-injury.
This can result in ongoing pain and loss of function.
It is often caused by sports related injuries, occupational overuse, aging and general health.
Chronic Achilles tendinosis affects both physically active and inactive individuals.
Tendinosis accounts for 30 to 50% of all sports injuries and 50% of occupation-related disorders in the United States.

What are tendons?

Tendons are specialized tissue that attach muscles to bones.
A normal healthy tendon is comprised mostly of water and a substance called collagen.
It is collagen that allows a tendon to flex and stretch.

Tendon_StructureIndividual collagen fibrils arrange themselves into bundles which are called collagen fibres.
 These fibres are arranged with other fibres to form a fascicle which group with other fascicles to form a tertiary fiber bundle.
Tertiary bundles grouped together form the tendon itself.
 Contained in between the tertiary bundles, fascicles and fibrils are nerve fibers, blood and lymph vessels.
 A cross section of a tendon shows a highly organized pattern of structures which reflect the function of the tendon.
The network of nerve fibers, blood and lymph vessels communicate with each other to detect and respond to loads applied to the tendon.

There are cells in the structures of a tendon that help maintain and repair the tendon in response to degradation from aging or damage.
When mechanical loads exceed the strength of a tendon, which may be compromised by aging or previous injury, small tears in the network of collagen structures may occur.
In response to damage, cells within the tendon attempt to repair the collagen network.
However, such repairs tend to be incomplete and an injured tendon never returns to its original state.

Tendon Injuries

Tendon injuries can be caused by factors such as age, body weight and nutrition.
They can also be caused from forces related to sports injuries, excessive loading, poor training techniques and environmental conditions.
A common form of tendon injury is called tendinitis.
Tendinitis is a tendon injury that has happened quickly (quick onset or acute) and is associated with pain and swelling.
With rest and appropriate treatment; tendinitis usually heals completely over a period of a few weeks.

Achilles-tendinosis

By contrast, tendinosis is a tendon disorder related to accumulation of small tears in the tendon structure over time with little, if any, inflammation.
Accumulated injuries can result in the formation of a disrupted collagen fibre network, because cells within a tendon do not completely repair damage.
Critically, the new collagen produced in response to an injury is abnormal in structure and composition leaving the tendon weakened with a decreased load bearing tolerance.
An improperly healed tendon is prone to further injuries including significant exposure to rupture because it does not return to its original strength.

In chronic Achilles tendinosis, pain and reduced function are part of a worsening cycle of healing and re-injury.
This cycle often ends with few pain free and functional periods and the injury enters a degenerative stage.
The poorly structured network of collagen structures in tendinosis result in a reduction in the overall tendon strength.
This can often result in re-injury or complete tendon rupture.

Treatment of Tendon Injuries

Slow healing and chronic debilitating pain is difficult to improve or manage with currently available treatments for tendinosis.
Some common approaches involve physiotherapy, drugs, injections of steroids or other products or other forms of therapy.
The effectiveness of these proposed treatments are often debated.
None of the methodologies offer a satisfactory recovery from tendinosis and often leave patients demobilized for several months during treatment.
Therefore, advancement in how we treat tendinopathy is urgently needed.
 Click here  to learn about a clinical research study being conducted in tendinosis.

#repetitivestraininjury #rsi #tendinosis #tendinopathy #tendinitis #carpaltunnel #carpaltunnelsyndrome #stemcells #mesenchymalstemcells
Have you suffered from chronic pain in your Achilles tendon for more than six months? If you do, you might be suffering from chronic Achilles tendinosis. Chronic Achilles tendinosis is a degenerative disease of the tendon. It is caused by a cycle of injury, improper healing and re-injury.
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
New Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness - Paper entitled "Hair Follicle Dermal Stem Cells Regenerate the Dermal Sheath, Repopulate the Dermal Papilla, and Modulate Hair Type" published journal Developmental Cell

"Hair Follicle Dermal Stem Cells Regenerate the Dermal Sheath, Repopulate the Dermal Papilla, and Modulate Hair Type" published in the peer-reviewed journal Developmental Cell (31, 543-558, December 8, 2014) (http://dx.doi.org/10.1016/j.devcel.2014.10.022)

http://www.cnbc.com/id/102288358

#alopecia #hairloss #hairlosstreatment #dermalsheathcells #stemcells #replicel #baldness #vancouver #canada  
VANCOUVER, Dec. 22, 2014/ PRNewswire/- RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further...
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
"Health Canada Issues “No Objection Letter” for RepliCel’s Phase 1/2 Clinical Trial of RCT-01

RepliCel Life Sciences Inc.
(OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has received a No Objection Letter from Health Canada providing its clearance to proceed with the Company’s proposed phase 1/2 clinical trial investigating the use of RCT-01 to treat patients suffering from chronic Achilles tendinosis.
The study entitled, “A randomized, double-blind, placebo-controlled, single-centre study to evaluate the efficacy and safety of RCT-01 in men and women with unilateral, chronic Achilles tendinosis” (known as the “ReaCT” study), investigates the potential of RCT-01 to treat chronic tendon injury.
The ReaCT study has been submitted to the University of British Columbia (UBC) Clinical Ethics Review Board (CREB) for its review and required approval prior to study initiation at the University of British Columbia Hospital.

The ReaCT study is anticipated to include 28 participants who will receive either an injection of RCT-01 or placebo (on a 3:1 treatment-to-placebo ratio) directly into the Achilles tendon using ultrasound guided imaging.
Participants’ overall health and tendinosis will be monitored over a six month period while they undergo post-treatment therapy to help facilitate recovery from their Achilles tendinosis.
Depending on the time required to enrol the study participants, the Company anticipates this treatment follow-up period could be complete as early as the latter part of 2015.
To learn more about the study please visit http://www.tendonstudy.com.

“Health Canada’s No Objection Letter for RepliCel’s ReaCT trial within 30 days of the Company’s first clinical trial application not only supports the technology, but evidences the great work done by the clinical team in terms of the trial design,” commented Dr.
Ross Davidson, Chair of RepliCel’s RCT-01 Clinical Advisory Board and retired Clinical Professor, Department of Orthopaedics, UBC.
“I have seen first-hand the limitations of the current standard of care for a significant percentage of chronic tendinosis patients whom remain refractory to any available treatment.
The ReaCT trial marks a milestone in the advancement of regenerative medicine for the treatment of tendinosis and offers the very distinct possibility of a new treatment paradigm for this difficult and often debilitating condition.
I expect this trial focused on chronic Achilles tendinosis to be the first step in addressing other debilitating tendon injuries in the future,” concluded Dr.
Davidson.

“The design of this trial has benefited from contributions from an outstanding group of key opinion leaders, including our clinical advisors and principal investigators, who provided expertise on the trial’s design, implementation, and several other critical parameters,” stated David Hall, President and CEO of RepliCel.
“The ReaCT trial represents an important step in the development of a series of products based on our non-bulbar dermal sheath (NBDS) fibroblast technology platform with the potential to address large commercial markets in the areas of musculoskeletal injury and disease.
In conclusion, the initiation of the ReaCT trial triggers a significant series of asset-building steps over the next 18 months covering clinical and business milestones.”

RCT-01 is the first of two products from RepliCel’s NBDS fibroblast platform currently slated to be tested in clinical trials in 2015.
Subject to regulatory clearance, the second product, RCS-01, will be evaluated as a potential treatment for aged and sun-damaged skin.
The Company anticipates filing this clinical trial application with the German competent regulatory authority in the near future.
RepliCel’s NBDS fibroblast program is a broad platform that has the potential to extend into other indications characterized by impaired tissue healing and a deficit of type 1 collagen.

RepliCel is actively targeting commercialization partners for both of these products, particularly in Asian markets.
The Company owns all rights to these product candidates and is in active prosecution of a full spectrum of intellectual property protection around key aspects of the cell source, manufacturing, use and composition of matter.

The RCT-01 and RCS-01 trials are in addition to the Company’s proposed phase 2 clinical trial evaluating RCH-01 for the treatment of pattern baldness; a trial the Company anticipates will involve over 160 patients and launch early next year in conjunction with Shiseido’s clinical trial of the same product in Japan under the terms of its co-development and licensing agreement with RepliCel.

About Chronic Achilles Tendinosis
Chronic Achilles tendinosis is a degenerative disease of the tendon.
It is caused by a cycle of injury, improper healing and re-injury.
It can result in ongoing pain and loss of function.
Tendinosis is often caused by sports related injuries, occupational overuse, aging and poor general health.
Chronic Achilles tendinosis affects both physically active and inactive individuals accounting for 30 to 50% of all sports injuries and 50% of occupation-related disorders in the United States.

Healthy functioning tendon is comprised largely of highly structured type 1 collagen supported by the repair and maintenance functions of resident fibroblasts.
In chronic tendinosis, it is believed that the resident fibroblast population is insufficient to complete the required healing.
The basis of the RCT-01 treatment is to augment the resident fibroblast population in the damaged tendon with fibroblasts derived from the patient’s own hair follicle.
These particular fibroblasts are easily isolated and expanded in addition to being highly expressive of the type 1 collagen and other extracellular proteins needed to reignite the healing process and support the regeneration of tendon for patients suffering from chronic tendinosis.

About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
The Company’s RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aging skin, and pattern baldness.
All product candidates are based on RepliCel’s innovative technology utilizing cell populations isolated from a patient’s own healthy hair follicles.
The Company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications.
The Company’s product pipeline is comprised of multiple clinical trials anticipated to launch through Q1 2015 in addition to Shiseido’s own clinical trial of RCH-01 and the device in late prototype development.
Visit http://www.replicel.com for additional information."

#repetitivestraininjury #rsi #tendinosis #tendinopathy #tendinitis #carpaltunnel #carpaltunnelsyndrome #stemcells #mesenchymalstemcells  
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
 
#BJSM  Open Access review:

#Tendons   - Time to revisit inflammation

http://bjsm.bmj.com/content/48/21/1553.full
 Next Section Abstract It is currently widely accepted among clinicians that chronic tendinopathy is caused by a degenerative process devoid of inflammation. Current treatment strategies are focused on physical treatments, peritendinous or intratendinous injections of blood or blood products and interruption of painful stimuli. Results have been at best, moderately good and at worst a failure. The evidence for non-infammatory degenerative process...
1
Add a comment...

Jeff Kang
owner

Discussion  - 
Rand said Simon would not have pitched if he had any sort of structural damage in his knee and that the knee issue is something Simon has been dealing with for some time.
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
>RepliCel receives important approvals for dermal rejuvenation clinical trial - "will have two clinical trials using NBDS-fibroblasts underway; RCT-01 in Canada (type 1 collagen and elastin for tendinosis) and RCS-01 in Germany (type 1 collagen for aged and sun-damaged skin)"

>RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial
 
German-based trial to test RCS-01 cell therapy treatment for aged and sun-damaged skin
 
VANCOUVER, BC – July 21, 2015 – RepliCel Life Sciences Inc.
(OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced it has received two important approvals required to conduct its RCS-01 phase 1 human clinical trial.
The first is from the Ethics Committee of the Faculty of Medicine Heinrich-Heine Universität Duesseldorf, a criteria for clinical trial initiation, and the second is approval from the Leibniz-Institut for its Tissue Procurement Authorization (TPA).
Ethics Committee approval and TPA are two parts of a three-part Clinical Trial Application (CTA) approval process required to conduct human clinical trials in Germany.
The final approval required is from the Paul Ehrlich Institute (PEI), the German regulatory body.
If cleared to proceed, the proposed trial will be conducted at the IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany.
RepliCel’s non-bulbar dermal sheath-derived fibroblast therapy entitled RCS-01 provides a promising treatment for intrinsically or extrinsically aged/damaged skin by providing UV-naïve collagen-producing cells directly to affected areas.
RepliCel’s unique manufacturing technology allows for isolation of fibroblasts derived from anagen-hair follicle mesenchymal tissue, which elicit more efficient replication potential in culture.
Furthermore, the proprietary culture conditions in which RCS-01 is manufactured enables these cells to maintain plasticity.
This plasticity allows the cells to adapt to the microenvironment and respond to the mechanical or surrounding stimuli after injection, leading to robust production of type 1 collagen and elastin and their proper alignment within the tissue.
For more information on this trial, please visit www.clinicaltrials.gov.
“The market for dermal fillers currently represented almost 6 million procedures and expenditures of almost $2 billion in 2013 according to statistics provided by the American Society of Plastic Surgeons.
RCS-01 could disrupt this market by providing patients with a filler comprised of their own fibroblast cells – a much more compelling long-term solution than hyaluronic acid which dissipates in approximately six months,” commented Dr.
Rolf Hoffmann, Chief Medical Officer.
“Successfully treating aged and sun damaged skin with our therapy would allow a patient to have a renewed dermal appearance by repopulating the patient’s aged and depleted fibroblast cells which are the key cells responsible for maintaining and repairing the skin’s extracellular matrix.”
“These two important approvals bring us closer to initiation of our RCS-01 clinical trial.
Approval from the PEI will enable us to immediately begin the recruitment phase of our trial.
With the initiation of this study, we will have two clinical trials using our NBDS-fibroblasts underway; RCT-01 in Canada and RCS-01 in Germany,” stated David Hall, CEO.
 
Trial Design

The study is anticipated to include 30 participants (24 treated, 6 placebo), male and female, who will receive either an injection of RCS-01 or placebo (on a 4:1 treatment-to-placebo ratio).
The primary purpose of this study is to assess the safety profile of RCS-01 injections compared to placebo injection at 6 and 12 months.
The study will also measure the impact these injections will have on skin markers related to aging through evaluation of gene expression profiles at 3 and 6 months.
16 participants will be biopsied for gene expression of skin aging markers and 12 participants biopsied for histopathology analysis to assess structural characteristics and molecular markers associated with skin aging.
This trial design is intended to deliver biologic data related to how, and the degree in which the product injection improves the fullness of the extracellular matrix supporting the skin.
This data will be critical to designing future trials intended to affect the skin’s appearance in areas of aesthetic importance.
 

About Aging Skin

The dermis and epidermis components of the skin lose thickness with age.
Solar radiation, particularly UVA, is known to penetrate deep into the dermal layer, damaging fibroblasts, which are the major cellular component of the dermis.
Similarly, there are some studies reporting that air pollutants/nanoparticles may also penetrate transepidermally, negatively impacting the dermal layer.
The damage caused by external stimuli include DNA strand breaks and mutations, which, if not repaired properly, can lead to cell death.
Similarly, oxidative stress caused by smoking leads to not only damages to DNA but also to other cellular components such as proteins and lipids.
Accumulation of damages to cellular proteins and DNA from years of exposure to extrinsic insults can lead to physiological changes to the skin that are naturally-irreversible.
Such changes are often associated with reduction in fibroblasts, disorganization of collagen fibrils and decreased production of collagen, elastin and other glycoproteins that provide structural support and stability to the extra cellular matrix “ECM” network.
Such changes to the dermal components are detrimental to maintaining mechanical tensile ability and structural integrity of the skin.
 
About RepliCel Life Sciences

RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
The company’s RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aging skin, and pattern baldness.
All product candidates are based on RepliCel’s innovative technology utilizing cell populations isolated from a patient’s own healthy hair follicles.
The company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications.
 The company’s product pipeline is comprised of multiple clinical trials anticipated to launch through Q1 2015 in addition to Shiseido’s own clinical trial of RCH-01 and the device in late prototype development.
Visit www.replicel.com for additional information.

#repetitivestraininjury #rsi #tendinosis #tendinopathy #tendinitis #carpaltunnel #carpaltunnelsyndrome #stemcells #mesenchymalstemcells
German-based trial to test RCS-01 cell therapy treatment for aged and sun-damaged skin VANCOUVER, BC – July 21, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced it has received two important approvals required to conduct its RCS-01 …
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
Glasgow Scientists trialling new therapy (TenoMiR) for tendinopathy. Loss of miR29a from human tendons results in increase in collagen type-3 production; a key feature of tendon disease. Replacement of miR-29a in damaged tendon cells in laboratory restores collagen production to pre injury levels

Scientists are investigating a new therapy for the treatment of tendon injuries such as tennis elbow and Achilles tendinitis after gaining new insight into the condition.
 
Tendon injuries (tendinopathies) are common, accounting for 30-50% of all sporting injuries, and are usually caused by repetitive strain or major trauma.
 
While many people recover after a period of rest, a significant number of people do not because the structure of the tendon itself has permanently weakened.
 
Healthy tendons, connecting muscles to bones, are primarily composed of type-1 collagen, a very strong material.
 
When injured the body responds by producing the inferior type-3 collagen to quickly repair the damage.
 
This type of collagen is not as strong as type-1 and is more prone to damage.
 
Normally, over time, type 3 is replaced by the stronger type-1.
 
However, in some people, repetitive damage means the body never replaces the weaker type-3 collagen, leaving them with inherently weaker tendons and long-term symptoms, such as pain and reduced mobility.
 
Scientists at the University of Glasgow are trialling a new therapy (TenoMiR™) for treating tendinopathy after being awarded a High Growth Spinout grant from Scottish Enterprise.
 
The trial will use injections of microRNA – small molecules that help regulate gene expression – into the tendon to ‘dial-down’ the production of type 3 collagen and switch to type-1.
 
The Glasgow team have already been successful in making the switch in cultured cells in the lab and in mice.
 
They will now work with international collaborators to trial the treatment on horses, which also frequently suffer tendon injuries, particularly in racing.
 
Following this trial, the team intends to commercialise the treatments through a spin-out company called Causeway Therapeutics focussing on bringing safe and effective medicines to human and veterinary markets.
 
Neal Millar, an academic consultant orthopaedic surgeon and clinical senior research fellow at the University of Glasgow, said: “Tendinopathy is essentially the result of an imbalance between collagen type-1 and type-3 and we have discovered the molecular cause.
 
This breakthrough has allowed us to find a way to alter the levels of collagen type-3 in tendons, with the ultimate aim to get patients with tendon injuries better quicker."
 
Co–investigator and senior molecular biologist Dr Derek Gilchrist commented that: “Our studies have revealed the previously unrecognised ability of a single microRNA to cross-regulate important functions in the early biological processes that lead to tissue repair.”
 
Results of the previous studies by the team, which also includes Professor Iain McInnes, Director of the Institute of Infection, Immunity and Inflammation within the University are published in Nature Communications and reveal the role of the microRNA 29a in tendon tissue repair.
 
The scientists found that a single microRNA - miR-29a – through its interaction with a protein, interleukin 33, plays a key role in regulating the production of collagens in tendon disease.
 
Loss of miR29a from human tendons results in an increase in collagen type-3 production; a key feature of tendon disease.
 
Replacement of miR-29a in damaged tendon cells in the laboratory restores collagen production to pre injury levels.
 
The research was supported by the Scottish Funding Council, Wellcome Trust and the Academy of Medical Sciences.
 
Reference: Millar, N.L., Gilchrist, D.S., Akbar, M., Reilly, J.H., Kerr, S.C., Campbell, A.L., Murrell, G.A.C., Liew, F.Y., Kurowska-Stolarska, M., McInnes, I.B. MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. Nature Communications 6, article no. 6774 (2015). doi:10.1038/ncomms7774


http://www.gla.ac.uk/news/headline_401460_en.html

#repetitivestraininjury #rsi #tendinosis #tendinopathy #tendinitis #carpaltunnel #carpaltunnelsyndrome
Scientific breakthrough unlocks potential novel tendon therapy. Issued: Mon, 13 Apr 2015 07:00:00 BST. Scientists are investigating a new therapy for the treatment of tendon injuries such as tennis elbow and Achilles tendinitis after gaining new insight into the condition.
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
>We also have a goal to do the geographic [licence 0:03:23] for our NBDS fibreglass platform, geographic licence in Asia, in particular focused on Japan, and we will begin discussions around the generation two licence.
>Our final goal essentially is to enter the US focused on NBDS programme for patellar tendinosis, and we are targeting discussions with the US military for that programme.

#tendinosis #patellartendinos #kneepain #kneeproblems #kneepaintreatment  
David Hall Chief Executive Officer Replicel
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
 
Scientists Grow Hair Using Stem Cells
For the first time, scientists has found a way to convert human stem cells into a type of cell that is capable of initiating hair growth. 

For the study, scientists started off by turning these human embryonic stem cells into neural crest cells, which are a type of cell that appear early on in development and that turn into cells of the nervous system, pigment-containing cells and components of the skeletal system, among other things. Then, they converted these cells into dermal papillae cells, which are known to regulate hair follicle formation and growth cycle.

These cells were then transplanted under the skin of immunodeficient “nude” mice, which as the name suggests lack body hair. These mice are useful in scientific research because they can receive grafts and transplants without rejecting the tissue. The researchers found that the cells were able to induce hair follicle formation in the mice, and were much more useful than transplanted dermal papillae which were isolated straight from human scalps. That’s because these cells can’t be obtained in sufficient quantities and quickly lose their ability to induce hair follicle formation when grown in dishes.

“The method is a marked improvement over current methods that rely on transplanting existing hair follicles from one part of the head to another,” lead scientist Alexey Terskikh said. “Our stem cell method provides an unlimited source of cells from the patient for transplantation and isn’t limited by the availability of existing hair follicles.”

via: http://goo.gl/1AR0HF
scholar article: http://goo.gl/BtjuVc
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
RepliCel Life Sciences is developing an autologous cell-based product for the treatment of chronic Achilles tendinosis. http://ow.ly/Fnv9t
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
>"WorkRite keyboard trays use a ball-bearing mounting track (with the standard Pinnacle 2 arm) which is the primary difference between their system and Humanscale’s.
This small design touch results in smoother action when adjusting the system and greater ease of use.

Best Value
WithinReach - $89.95

Highest Quality
Humanscale - $299.00
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
 
My custom-built ergonomic split-keyboard + vertical mouse setup. (The desk is a temporary setup while I'm in Sydney visiting my Mum's house, but the keyboard & mouse travel with me). The keyboard pyramid is made out of 2 USB keyboards simply attached together with flexible rubber like a hinge, with a piece of string holding the 2 keyboards at a fixed angle that I can adjust. (You can't really see the string but it is attached to 2 screws in the back, halfway up the keyboards). Combined with a 3M vertical mouse (the joystick looking thing next to the keyboard pyramid) and a really simple Linux script I wrote that locks me out of my computer every time I've used it for 10 minutes, this setup allowed me to get rid of very bad RSI in my hands. It took about 9 months of using this combination before my RSI actually went away, but now I've been using it everyday for several years, and I literally wouldn't be able to use computers without this setup, so it clearly works!
1
Add a comment...

Jeff Kang
owner

Discussion  - 
 
Ultrasound enhancement provides clarity to damaged tendons, ligaments

#tendinosis #tendinitis #tendinopathy 
Sabrina Brounts (front), clinical associate professor of large animal surgery, uses ultrasound to gauge how well a Missouri Fox Trotter horse is healing. Also pictured (left to right) are large animal specialty intern Jennifer Whyard and fourth-year students Ben Tegen and Daniel Kieler.
1
Add a comment...